101. GSG2 promotes progression of human endometrial cancer by regulating PD-1/PD-L1 expression via PI3K-AKT pathway.
- Author
-
Chen, Hong, Liu, Shuxi, Wu, Sikao, Nong, Xianxian, Liu, Naiyu, and Li, Li
- Subjects
- *
ENDOMETRIAL cancer , *PROGRAMMED cell death 1 receptors , *PROGRAMMED death-ligand 1 , *CARCINOGENS , *CELL anatomy , *DNA repair - Abstract
• GSG2 has tumor-promoting properties in the development of Endometrial carcinoma. • GSG2 regulates the total number of immune cells and the structure of immune cells in the tumor microenvironment. • GSG2 knockdown affects the functions of CD4 T cells. • GSG2 regulates PD-1/PD-L1 expression directly or indirectly through PI3K/AKT pathway. Cell cycle dysregulation leading to uncontrolled growth is a primary characteristic of malignancy. GSG2, a mitosis-related kinase, affects the normal cell cycle by interfering with the normal dissociation of centromere cohesion, and its overexpression has been shown to play an important role in cancer cells. Here, we investigated the function of GSG2 as a tumor promoter in endometrial carcinoma and its relationship with the immunological microenvironment. We used immunohistochemistry to identify a correlation between the development and prognosis of GSG2 and endometrial cancer. Cell and animal experiments confirmed that GSG2 has a protumorigenic phenotype in endometrial cancer cell lines. Furthermore, using GeneChip analysis and a tumor-immune coculture model, we observed a link between GSG2 expression and the composition of the immune microenvironment. Therefore, we concluded that the activation of the PI3K/AKT pathway by GSG2 may impact DNA repair, disrupt the cell cycle, and regulate the immune response, all of which could increase the ability of EC cells to proliferate malignantly. Consequently, it is anticipated that GSG2 will be a viable therapeutic target in endometrial carcinoma. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF